Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 368

1.

Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4'-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide.

Trapella C, Fischetti C, Pela' M, Lazzari I, Guerrini R, Calo' G, Rizzi A, Camarda V, Lambert DG, McDonald J, Regoli D, Salvadori S.

Bioorg Med Chem. 2009 Jul 15;17(14):5080-95. doi: 10.1016/j.bmc.2009.05.068. Epub 2009 Jun 2.

PMID:
19527931
2.

Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24.

Fischetti C, Camarda V, Rizzi A, Pelà M, Trapella C, Guerrini R, McDonald J, Lambert DG, Salvadori S, Regoli D, Calo' G.

Eur J Pharmacol. 2009 Jul 1;614(1-3):50-7. doi: 10.1016/j.ejphar.2009.04.054. Epub 2009 May 12.

PMID:
19445927
3.

Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.

Spagnolo B, Carrà G, Fantin M, Fischetti C, Hebbes C, McDonald J, Barnes TA, Rizzi A, Trapella C, Fanton G, Morari M, Lambert DG, Regoli D, Calò G.

J Pharmacol Exp Ther. 2007 Jun;321(3):961-7. Epub 2007 Feb 28.

4.

[Nphe1,Arg14,Lys15]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor.

Calo G, Rizzi A, Rizzi D, Bigoni R, Guerrini R, Marzola G, Marti M, McDonald J, Morari M, Lambert DG, Salvadori S, Regoli D.

Br J Pharmacol. 2002 May;136(2):303-11.

5.

[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor.

Carrà G, Rizzi A, Guerrini R, Barnes TA, McDonald J, Hebbes CP, Mela F, Kenigs VA, Marzola G, Rizzi D, Gavioli E, Zucchini S, Regoli D, Morari M, Salvadori S, Rowbotham DJ, Lambert DG, Kapusta DR, Calo' G.

J Pharmacol Exp Ther. 2005 Mar;312(3):1114-23. Epub 2004 Oct 27.

6.
7.

In vitro and in vivo pharmacological characterization of the nociceptin/orphanin FQ receptor ligand Ac-RYYRIK-ol.

Gündüz O, Rizzi A, Baldisserotto A, Guerrini R, Spagnolo B, Gavioli EC, Kocsis L, Magyar A, Benyhe S, Borsodi A, Calò G.

Eur J Pharmacol. 2006 Jun 6;539(1-2):39-48. Epub 2006 Apr 5.

PMID:
16682024
8.
9.

Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4).

Volta M, Marti M, McDonald J, Molinari S, Camarda V, Pelà M, Trapella C, Morari M.

Peptides. 2010 Jun;31(6):1194-204. doi: 10.1016/j.peptides.2010.03.015. Epub 2010 Mar 20.

PMID:
20307605
10.

Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.

Rizzi A, Gavioli EC, Marzola G, Spagnolo B, Zucchini S, Ciccocioppo R, Trapella C, Regoli D, Calò G.

J Pharmacol Exp Ther. 2007 Jun;321(3):968-74. Epub 2007 Feb 28.

11.
12.

Novel potent agonist [(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 and antagonist [Nphe1,(pF)Phe4,Aib7,Aib11,Arg14,Lys15]N/OFQ-NH2 of nociceptin/orphanin FQ receptor.

Peng YL, Chang M, Dong SL, Li W, Han RW, Fu GX, Chen Q, Wang R.

Regul Pept. 2006 May 15;134(2-3):75-81. Epub 2006 Mar 6.

PMID:
16516988
14.

The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510).

Varty GB, Lu SX, Morgan CA, Cohen-Williams ME, Hodgson RA, Smith-Torhan A, Zhang H, Fawzi AB, Graziano MP, Ho GD, Matasi J, Tulshian D, Coffin VL, Carey GJ.

J Pharmacol Exp Ther. 2008 Aug;326(2):672-82. doi: 10.1124/jpet.108.136937. Epub 2008 May 20.

15.

Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol.

Bojnik E, Babos F, Fischetti C, Magyar A, Camarda V, Borsodi A, Bajusz S, Calo' G, Benyhe S.

Brain Res Bull. 2010 Mar 16;81(4-5):477-83. doi: 10.1016/j.brainresbull.2009.09.013. Epub 2009 Oct 2.

PMID:
19800951
16.

N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.

Guerrini R, Caló G, Lambert DG, Carrá G, Arduin M, Barnes TA, McDonald J, Rizzi D, Trapella C, Marzola E, Rowbotham DJ, Regoli D, Salvadori S.

J Med Chem. 2005 Mar 10;48(5):1421-7.

PMID:
15743186
17.

Acute and chronic antiparkinsonian effects of the novel nociceptin/orphanin FQ receptor antagonist NiK-21273 in comparison with SB-612111.

Marti M, Mela F, Budri M, Volta M, Malfacini D, Molinari S, Zaveri NT, Ronzoni S, Petrillo P, Calò G, Morari M.

Br J Pharmacol. 2013 Feb;168(4):863-79. doi: 10.1111/j.1476-5381.2012.02219.x.

18.

Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.

Khroyan TV, Polgar WE, Jiang F, Zaveri NT, Toll L.

J Pharmacol Exp Ther. 2009 Dec;331(3):946-53. doi: 10.1124/jpet.109.156711. Epub 2009 Aug 27.

19.

Pharmacodynamic characterization of ZP120 (Ac-RYYRWKKKKKKK-NH2), a novel, functionally selective nociceptin/orphanin FQ peptide receptor partial agonist with sodium-potassium-sparing aquaretic activity.

Kapusta DR, Thorkildsen C, Kenigs VA, Meier E, Vinge MM, Quist C, Petersen JS.

J Pharmacol Exp Ther. 2005 Aug;314(2):652-60. Epub 2005 Apr 26.

20.

Novel hexahydrospiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptor agonists.

Kolczewski S, Adam G, Cesura AM, Jenck F, Hennig M, Oberhauser T, Poli SM, Rössler F, Röver S, Wichmann J, Dautzenberg FM.

J Med Chem. 2003 Jan 16;46(2):255-64.

PMID:
12519064

Supplemental Content

Support Center